Replies to post #46142 on Coretec Group Inc (CRTG)

[Testpilot]

Perfect—let’s quantify this cleanly and realistically so you can see what CRTG could be worth depending on how DKME plays out.

?

📊 CRTG Valuation Model (Tied to DKME Outcome)

We’ll use your commonly referenced assumptions:

* Shares Outstanding:
* Case A: 1.1B shares
* Case B: 1.7B shares
* Revenue assumptions:
* Core Optics: $16M
* DKME:
* Bear: $0 (fails / not real)
* Base: $50M
* Bull: $100M+
* Multiples (conservative for micro/small cap):
* 0.5x (distressed/speculative)
* 1.0x (low-normal)
* 2.0x (growth narrative)

?

🔴 SCENARIO 1 — DKME FAILS (Bear Case)

Revenue:

* ~$16M (Core Optics only)

Valuation:

* 0.5x ? $8M
* 1.0x ? $16M

Share Price:

1.1B shares:

* $8M ? $0.007
* $16M ? $0.015

1.7B shares:

* $8M ? $0.0047
* $16M ? $0.009

👉 Reality check:
This is basically microcap survival mode

?

🟡 SCENARIO 2 — DKME PARTIALLY VALIDATED (Base Case)

Revenue:

* $16M (Core Optics) + $50M (DKME) = $66M

Valuation:

* 0.5x ? $33M
* 1.0x ? $66M
* 2.0x ? $132M

Share Price:

1.1B shares:

* $33M ? $0.03
* $66M ? $0.06
* $132M ? $0.12

1.7B shares:

* $33M ? $0.019
* $66M ? $0.039
* $132M ? $0.078

👉 This is where things start getting interesting—but still needs proof

?

🟢 SCENARIO 3 — DKME FULLY VALIDATED (Bull Case)

Revenue:

* $16M + $100M = $116M

Valuation:

* 1.0x ? $116M
* 2.0x ? $232M
* 3.0x ? $348M (if hype + growth story kicks in)

?

Share Price:

1.1B shares:

* $116M ? $0.105
* $232M ? $0.21
* $348M ? $0.32

1.7B shares:

* $116M ? $0.068
* $232M ? $0.136
* $348M ? $0.20

?

⚠️ CRITICAL REALITY CHECK

The ENTIRE model depends on ONE thing:

👉 Is DKME real, verifiable, and economically tied to CRTG?

Without that:

* The bull case collapses
* Even the base case becomes questionable

?

🔍 Red Flag Checklist (You Should Watch Closely)

If these show up ? strong confirmation:

✅ Positive Signals

* Audited financials (not just claims)
* Clear ownership structure
* Revenue breakdown with customers
* KRX approval outcome
* Board / control linkage confirmed

?

🚩 Warning Signs

* Continued delays with no clarity
* Vague press releases
* No audited numbers
* Complex or unclear ownership chain
* Heavy reliance on “future projections”

?

🧠 Strategic Take (Straight Talk)

Right now you’re looking at:

A binary asymmetric setup

Upside:

* 5x–20x potential (if validated)

Downside:

* Stays sub-penny / stagnates (if not)

?

📌 Bottom Line

* This KRX delay = decision point approaching
* You are early—but also in high uncertainty
* The next committee decision is the pivot

[Juststoppingby]

When Coretec files all its delinquent filings to bring them current with the SEC and back on normal trading, DKME won't be part of that. It will be Core Optics and Endurion that shine a light on Coretec Group.
Once they become current with the SEC, then I believe they will acquire DKME Co., Ltd. through DKME Inc.

Let's see what that will look like with only Core Optics and Endurion.

What the SEC will expect once Coretec becomes current. Let’s walk through how Endurion must appear in those pro forma filings, and why the March 14, 2024, transcript language makes that disclosure unavoidable.

🧾 1. Why Endurion qualifies as a reportable segment
Under Reg S-K Item 101 and ASC 280 (Segment Reporting), any business line that:
- has distinct technology or markets,
- has identifiable assets or R&D expenditures, and
- is expected to generate future revenue
must be described separately in the Business and MD&A sections of SEC filings.
Endurion meets all three tests:
- proprietary silicon-anode IP,
- separate R&D and partner evaluation activity,
- defined commercialization timeline (2027).
So when Coretec files its catch-up 10-Ks and 10-Qs in May–July 2026, Endurion will appear as a named segment alongside Core Optics.

🧩 2. How Endurion will appear in the pro forma financials
Form 8-K/A (Pro Forma Consolidation)
If Coretec consolidates Core Optics or any new entity, the pro forma must include:
- R&D capitalization or expense lines for Endurion,
- any deferred development costs,
- partner evaluation or JDA commitments,
- narrative explaining commercialization milestones.

Footnotes
Expect a note titled “Endurion Battery Technology Development” detailing:
- NDAs and JDAs under negotiation,
- material deliveries for evaluation,
- estimated commercialization horizon,
- accounting treatment (R&D vs. intangible asset).

MD&A
Management will have to discuss:
- progress since March 2024,
- technical validation results,
- market focus (military, EV, aerospace, eVTOL),
- funding requirements for pilot production.

🚀 3. Why the March 14, 2024, call forces disclosure
That transcript established Endurion as partner-validated and evaluation-ready, not speculative R&D.
Once a company publicly represents a technology as commercially near-term, the SEC expects follow-up disclosure showing:
- whether those JDAs were executed,
- whether material was delivered,
- whether commercialization remains on schedule.
Failing to include Endurion now would create a selective-disclosure gap—something auditors will flag immediately.

✈️ 4. Why aerospace, eVTOL, and military matter in filings
These sectors will appear in the Market Opportunities section because they:
- are early adopters of advanced battery materials,
- tolerate higher cost for performance gains,
- overlap with Core Optics’ existing customer base (camera modules, sensors).
That linkage lets Coretec present a coherent commercialization ecosystem: optics + battery + onboard systems.

💡 5. What investors will see in May–July 2026 filings

🎯 6. The key insight
> Once Coretec becomes SEC-current, Endurion moves from narrative to regulated disclosure.
> It will appear in the pro forma filings because the March 2024 statements created a material expectation of commercialization.
That inclusion transforms Endurion from a “story” into a reportable business segment, anchoring the 2026–2028 valuation trajectory we built earlier.